CD30 ADC · ADC
brentuximab vedotin
1 active trials, targeting CD30. Not approved for any biomarker on marked.bio yet.
Also known as SGN-35, Adcetris.
Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.
Biomarkers
| Biomarker | Active trials | All trials | Furthest active phase |
|---|---|---|---|
| ALK fusion | 1 | 6 | Phase 2 |
Trials
1 of 6 trials shown
-
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
vinblastinebrentuximab vedotinnivolumab
Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Criteria:
ALK fusionAnaplastic Large Cell Lymphoma, ALK-Positive
-
Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
brentuximab vedotincyclophosphamidedoxorubicinetoposideprednisone
Systemic anaplastic large cell lymphoma (ALCL) ALK+ with age-adjusted international prognostic index (aaIPI) ≥1
ALK fusionLymphoma, T-Cell, Peripheral
-
Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas
brentuximab vedotinBeEAM Regimen
…ubtypes such as Hodgkin lymphomas, angioimmunoblastic T-cell lymphomas (AITL), anaplastic ALK+ T-cell lymphomas, Sézary-syndrome, but also all other malignant CD30+ lymphoma types.
ALK fusionLymphoma
-
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
brentuximab vedotinceritinib FDA EU
Treatment-naive systemic ALK-positive ALCL patients
ALK fusionAnaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
-
Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
ALK+ ALCL
ALK fusionALK+ Anaplastic Large Cell Lymphoma
-
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
brentuximab vedotincrizotinib FDA EUcyclophosphamidecytarabinedexamethasonedoxorubicinetoposideIfosfamidemethotrexate
Disease must be anaplastic lymphoma kinase (ALK) positive (defined by local institutional standards)
ALK fusionAnaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
No trials match these filters.